Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2025 16:30 ET | Source: MannKind

MannKind Expands Executive Leadership Team

Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind...
December 18, 2024 07:00 ET | Source: MannKind

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH
December 16, 2024 06:05 ET | Source: MannKind

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
December 11, 2024 06:00 ET | Source: MannKind

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
November 07, 2024 16:02 ET | Source: MannKind

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
November 05, 2024 16:15 ET | Source: MannKind

MannKind to Present at 2024 UBS Healthcare Conference

MannKind to Present at 2024 UBS Healthcare Conference
November 04, 2024 06:05 ET | Source: MannKind

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
October 31, 2024 16:05 ET | Source: MannKind

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Mannkind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
October 30, 2024 21:00 ET | Source: MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease
September 30, 2024 06:00 ET | Source: MannKind

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN